Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.46 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.46 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 4/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14564141 | 0.89 | KMT2A (0.54) | KMT2AL3MBTL1NPFFR1NPFFR2KCNA3 | |
| SCHEMBL6169636 | 0.87 | KMT2A (0.55) | KMT2AL3MBTL1NPFFR1NPFFR2KCNA3 | |
| SCHEMBL1815532 | 0.84 | KMT2A (0.65) | KMT2AL3MBTL1NPFFR1NPFFR2KCNA3 | |
| SCHEMBL23779786 | 0.83 | KMT2A (0.55) | KMT2AL3MBTL1NPFFR1NPFFR2KCNA3 | |
| SCHEMBL6482327 | 0.83 | KMT2A (0.55) | KMT2AL3MBTL1NPFFR1NPFFR2KCNA3 | |
| SCHEMBL18980315 | 0.83 | KMT2A (0.55) | KMT2AL3MBTL1NPFFR1NPFFR2KCNA3 | |
| SCHEMBL20745275 | 0.82 | KMT2A (0.54) | KMT2AL3MBTL1NPFFR1NPFFR2KCNA3 | |
| SCHEMBL27172319 | 0.82 | ENPP2 (0.57) | KMT2AL3MBTL1MEN1ALDH1A1ENPP2 | |
| SCHEMBL555251 | 0.81 | KMT2A (0.62) | KMT2AL3MBTL1NPFFR1NPFFR2KCNA3 | |
| SCHEMBL17304781 | 0.81 | KMT2A (0.65) | KMT2AL3MBTL1NPFFR1NPFFR2KCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| WO-2023010078-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| WO-2021158698-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| EP-0871628-A1 | QUINOLIZINONE TYPE COMPOUNDS | Abbott Laboratories (US) | 1998-10-21 | — | — | EP | disclosed |
| WO-1996039407-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1996-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | CHRM4, CHRM2, CHRM5 | KMT2A 1920/4885L3MBTL1 4078/4885NPFFR1 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.